Our new mechanistic and functional data demonstrated an essential, general role for CRTC activation in maintaining the malignant phenotypes of LKB1-inactivated lung cancer and identified the CRTC-CREB interaction as a valuable molecular target for development of new therapies for lung cancer with LKB1 deficiency. Here, CREB1 is linked to lung carcinoma.